Xianming Jin

This inventor holds 21 USPTO granted patents and 8 published patent applications, plus 1 CIPO patent and 5 EPO patents, primarily in Protein Kinase Inhibitors. Top assignees: Novartis Ag, Array Biopharma Inc., Irm LLC. Active years: 2013-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Xianming Jin. Retrieved from https://idiyas.com/inventor/xianming-jin

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 21 (Patent Applications = 8)

% Patents Active = 81.0

CIPO Patents = 1 (Patent Applications = 2)

EPO Patents = 5 (Patent Applications = 5)

Average Co-Inventor Count = 7.4

ph-index = 6

Forward Citations = 110(Granted Patents)

Company Filing History:

where one patent can have more than one assignee

Years Active: 2013-2023

Loading Chart...

Areas of Expertise:

Protein Kinase Inhibitors

Antivirals

LpxC Inhibitors

Aminoheteroaryl Benzamides

Isoxazole Hydroxamic Acids

Fused Tricyclic Compounds

Tetracyclic Pyridone Compounds

Aminoheteroaryl Compounds

Pyrazolo-Dihydropyrazinyl-Pyridone

Isoxazoline Hydroxamic Acids

Compositions

Compounds

21 patents (USPTO):Sort by Forward CitationsExplore Patents

1. RE49556 - Compounds and compositions as protein kinase inhibitors (2023-06-19),

2. 11234977 - Fused tricyclic pyrazolo-dihydropyrazinyl-pyridone compounds as antivirals (2022-02-01),

3. 10660888 - Aminoheteroaryl benzamides as kinase inhibitors (2020-05-26),

4. 10576080 - Compounds and compositions as protein kinase inhibitors (2020-03-03),

5. 10568884 - Compounds and compositions as protein kinase inhibitors (2020-02-25),

6. 10188649 - Aminoheteroaryl benzamides as kinase inhibitors (2019-01-29),

7. 10093673 - Tetracyclic pyridone compounds as antivirals (2018-10-09),

8. 10029994 - Isoxazole hydroxamic acid compounds as LpxC inhibitors (2018-07-24),

9. 10005761 - Compounds and compositions as protein kinase inhibitors (2018-06-26),

10. 9850230 - Compounds and compositions as protein kinase inhibitors (2017-12-26),

11. 9850229 - Compounds and compositions as protein kinase inhibitors (2017-12-26),

12. 9845325 - Tetracyclic pyridone compounds as antivirals (2017-12-19),

13. 9815804 - Isoxazole hydroxamic acid compounds as LpxC inhibitors (2017-11-14),

14. 9763937 - Aminoheteroaryl benzamides as kinase inhibitors (2017-09-19),

15. 9718792 - Isoxazoline hydroxamic acid derivatives as LpxC inhibitors (2017-08-01),

Title: Unveiling the Innovations of Inventor Xianming Jin

Introduction:

In the realm of revolutionary inventions, one name shines bright - Xianming Jin, a distinguished inventor based in San Ramon, CA (US). With an impressive portfolio of 21 patents to his name, Jin has contributed significantly to the fields of medicine and antivirals.

Latest Patents:

Jin's latest patents showcase his expertise and ingenuity. One remarkable invention is the development of compounds and compositions as protein kinase inhibitors. These compounds have shown promising results in treating diseases associated with abnormal kinase activity. Another groundbreaking patent is the creation of fused tricyclic pyrazolo-dihydropyrazinyl-pyridone compounds as antivirals, particularly for combating hepatitis B virus infections.

Career Highlights:

Throughout his career, Xianming Jin has made his mark in renowned companies such as Novartis AG and Array Biopharma Inc. His dedication to innovation and scientific excellence has been instrumental in shaping the pharmaceutical landscape.

Collaborations:

Collaboration is key in the world of inventions, and Xianming Jin has worked alongside esteemed individuals like Daniel J Poon and Shenlin Huang. Together, they have pushed boundaries and paved the way for groundbreaking discoveries in the field.

Conclusion:

In conclusion, Xianming Jin emerges as a trailblazer in the realm of innovations and inventions. His relentless pursuit of excellence, coupled with his strategic collaborations, has cemented his position as a visionary inventor. The patents he holds stand as a testament to his commitment to advancing science for the betterment of society.

Profile summary based on public USPTO records.